<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antithrombin III concentration was studied in 86 patients with recurrent or extensive <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Two of them were found to have an hereditary <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>25 patients receiving <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy had low antithrombin III concentration </plain></SENT>
<SENT sid="3" pm="."><plain>After stopping <z:chebi fb="5" ids="28304">heparin</z:chebi> treatment antithrombin rose to a <z:mpath ids='MPATH_458'>normal</z:mpath> level </plain></SENT>
<SENT sid="4" pm="."><plain>Pathological antithrombin III modifications are recalled (synthesis decrease in <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e>, intra vascular consumption during active <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>Antithrombin III decreased activity induced by <z:chebi fb="5" ids="28304">heparin</z:chebi> treatment is pointed out </plain></SENT>
</text></document>